On March 20th, YIDU TECH continued its routine value-driven share repurchase initiative, utilizing over HK$5 million to buy back its shares. This consistent and decisive capital action persistently signals the company's strong confidence in its intrinsic value and the long-term prospects of the AI healthcare sector. As a pioneer in share buybacks within the Hong Kong-listed AI healthcare sector, the company's repurchase activity this year has led the market. It has conducted 34 repurchases year-to-date, with cumulative expenditures exceeding HK$240 million. This high-frequency, substantial buyback effort sets a benchmark for value within the Hong Kong stock market's healthcare technology segment. Combined with a high proportion of treasury shares, the company's financial stability and long-term value proposition are further accentuated.
Concurrently, the company is actively securing a leading position in its core business. YIDU TECH recently made a significant appearance at the CMAC Innovation Drug Development Conference, a premier industry event. It showcased its full-chain AI solutions for clinical research, hosting a dedicated academic salon to explore new AI-driven paradigms for CROs. The event featured demonstrations of key achievements in AI-empowered drug research and development, highlighting how the technology efficiently enhances the quality and reduces the costs of clinical studies. This accelerates the large-scale implementation of AI technology in drug R&D and clinical research scenarios, further solidifying the company's technological leadership in the industry.
With firm buybacks stabilizing market expectations on the capital front and strong industry presence reinforcing its competitive moat on the business front, YIDU TECH will continue to leverage its triple-driver strategy of "Capital + Technology + Application Scenarios." The company is committed to deepening its expertise in the core AI healthcare赛道, unleashing long-term growth potential, and delivering tangible returns to investors and market trust.